```html

Zollinger–Ellison Ulcer Disease: A Complete Patient Guide

Overview

Zollinger–Ellison ulcer disease (ZEUD), also called a Zollinger‑Ellison syndrome (ZES), is a rare condition in which one or more gastrin‑producing tumors (gastrinomas) develop in the pancreas or duodenum. These tumors secrete large amounts of the hormone gastrin, which overstimulates the stomach’s acid‑producing cells. The resulting hyperacidity leads to recurrent, often severe, peptic ulcers that can appear in atypical locations such as the jejunum.

Who it affects

• Both men and women; slight male predominance (≈55%).
• Average age at diagnosis: 45–55 years, but cases range from teens to elderly.
• About 25% occur in the setting of multiple endocrine neoplasia type 1 (MEN‑1), a hereditary syndrome.

Prevalence

ZEUD is very uncommon—estimated at 0.5–2 cases per million people per year worldwide <sup>[1]</sup>. Because the disease often remains undiagnosed for years, the true prevalence may be slightly higher.

Symptoms

Symptoms arise from excess gastric acid and from the tumor itself. Not all patients experience every sign.

Gastro‑intestinal symptoms

• Abdominal pain – usually a burning or gnawing sensation that may improve with food (duodenal ulcer pattern) or worsen after meals (gastric ulcer pattern).
• Refractory or recurrent ulcers – ulcers that persist despite standard proton‑pump inhibitor (PPI) therapy.
• Diarrhea – occurs in up to 60% of patients; may be watery, fatty, or contain blood.
• Steatorrhea (fatty stools) – due to acid‑induced inactivation of pancreatic enzymes.
• Nausea & vomiting – especially after large meals.
• Heartburn or gastro‑esophageal reflux disease (GERD) – from excessive acid.

Systemic / tumor‑related symptoms

• Weight loss – from malabsorption and chronic diarrhea.
• Fatigue – secondary to anemia (occurs in 30% of patients).
• Flushing or skin changes – rare, more common when the gastrinoma is part of MEN‑1.

Red‑flag features that suggest a complicated ulcer

• Bleeding (vomiting blood or black/tarry stools).
• Sudden, severe abdominal pain (possible perforation).
• Persistent vomiting that cannot keep food down.
• Unexplained rapid weight loss (>10 % body weight in 6 months).

Causes and Risk Factors

ZEUD is fundamentally a neuroendocrine tumor (NET) that secretes gastrin. The exact cause of sporadic gastrinomas is unknown, but several risk factors increase the likelihood of developing them.

Primary causes

1. Gastrin‑producing neuroendocrine tumors (gastrinomas) – usually <1 cm to 5 cm in size, located in:
   • Duodenum (≈55% of cases)
   • Pancreas (≈30%)
   • Rarely in the jejunum, lymph nodes, or bile duct.
2. Multiple endocrine neoplasia type 1 (MEN‑1) – an inherited mutation in the MEN1 gene. About 20–30% of ZEUD patients have MEN‑1, which also predisposes to parathyroid and pituitary tumors.

Risk factors

• Family history of MEN‑1 or gastrinomas.
• Genetic syndromes affecting the endocrine pancreas (e.g., MEN‑1, rarely von Hippel‑Lindau).
• Chronic atrophic gastritis or pernicious anemia – do NOT cause ZEUD, but can mimic hypergastrinemia and thus complicate diagnosis.
• Age > 40 years (peak incidence).

Diagnosis

Because the disease is rare and symptoms overlap with common peptic ulcer disease, a systematic approach is essential.

Step‑wise diagnostic work‑up

1. Clinical suspicion – refractory ulcer, ulcer distal to the duodenum, or ulcer with severe diarrhea.
2. Laboratory testing
   • Fasting serum gastrin level – a level > 1000 pg/mL (or > 10× upper limit) in the presence of gastric pH < 2 is highly diagnostic. Levels 200–1000 pg/mL require a secretin stimulation test.
   • Secretin stimulation test – paradoxical rise in gastrin after IV secretin confirms gastrinoma.
   • Basic metabolic panel, CBC (to assess anemia), and liver function tests.
3. Imaging studies
   • Endoscopic ultrasound (EUS) – high sensitivity for small pancreatic/duodenal lesions.
   • Multiphasic contrast CT or MRI – identifies primary tumor and liver metastases.
   • Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT – the gold standard for locating gastrinomas, especially when they are < 1 cm.
4. Upper endoscopy (EGD) – demonstrates ulcer location and may obtain biopsies to rule out H. pylori or malignancy.

According to the American College of Gastroenterology (2023), > 90% of ZEUD cases are diagnosed within 2–3 years of symptom onset when the above protocol is applied <sup>[2]</sup>.

Treatment Options

Management involves two parallel goals:

1. Control gastric acid hypersecretion.
2. Locate and treat the gastrinoma (surgery, targeted therapy, or observation).

Acid‑suppressive medications

• High‑dose proton‑pump inhibitors (PPIs) – e.g., omeprazole 40–80 mg daily or equivalent. PPIs normalize gastric pH and heal ulcers in > 95% of patients <sup>[3]</sup>.
• In refractory cases, potassium‑competitive acid blockers (PCABs) such as vonoprazan may be considered (off‑label).

Surgical management

Surgery offers a potential cure, especially for isolated tumors.

• Enucleation – removal of a small, well‑defined tumor without removing surrounding pancreas.
• Pancreaticoduodenectomy (Whipple procedure) – indicated for larger pancreatic head tumors.
• Distal pancreatectomy – for tumors in the pancreatic body/tail.
• In MEN‑1 patients with multiple tumors, a more conservative approach (e.g., enucleation of dominant lesions) is often chosen because complete resection is rarely curative.

Medical therapies for unresectable or metastatic disease

• Somatostatin analogues (octreotide, lanreotide) – suppress gastrin release and may shrink tumors.
• Targeted therapy – everolimus or sunitinib for progressive neuroendocrine tumors per NCCN guidelines.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE for somatostatin‑receptor positive disease.
• Chemotherapy – reserved for high‑grade neuroendocrine carcinomas (rare in ZEUD).

Lifestyle and adjunct measures

• Avoid non‑steroidal anti‑inflammatory drugs (NSAIDs), aspirin, and smoking – all aggravate ulcer formation.
• Limit alcohol intake (< 2 standard drinks/day for men, < 1 for women).
• Eat small, frequent meals to reduce gastric acid spikes.

Living with Zollinger–Ellison Ulcer Disease

Even after successful treatment, lifelong follow‑up is essential.

Medication adherence

• Take PPIs exactly as prescribed; missing doses can cause rebound hyperacidity.
• Arrange pharmacy refills in advance; many patients need twice‑daily dosing.

Monitoring

• Serum gastrin level and fasting gastric pH every 6–12 months (more often after surgery).
• Annual imaging (CT/MRI or ^68Ga‑DOTATATE PET) to detect recurrence or metastasis.
• Endoscopic surveillance every 2–3 years if ulcers persist.

Nutrition

• High‑protein, low‑fat diet helps counteract steatorrhea.
• Consider pancreatic enzyme supplements if fat malabsorption persists.
• Stay hydrated; oral rehydration solutions can replace electrolytes lost in chronic diarrhea.

Psychosocial support

Chronic disease can cause anxiety or depression. Counseling, support groups (e.g., NET patient organizations), and mindfulness practices improve quality of life.

Prevention

Because most gastrinomas are sporadic, primary prevention is limited. However, risk reduction strategies are still valuable:

• Genetic counseling for families with MEN‑1; early screening (annual fasting gastrin, imaging) can detect tumors before they become symptomatic.
• Avoid known ulcer‑aggravating agents (NSAIDs, high‑dose steroids).
• Maintain a healthy weight and limit alcohol to reduce overall gastric irritation.

Complications

If untreated or inadequately controlled, ZEUD can lead to serious health problems:

• Bleeding ulcers – may require endoscopic hemostasis or surgery.
• Perforation – an emergency situation causing peritonitis.
• Obstruction – from ulcer scarring or tumor growth.
• Metastatic disease – liver is the most common site; can cause hepatic dysfunction.
• Gastric carcinoids – chronic hypergastrinemia can stimulate enterochromaffin‑like cells.
• Nutritional deficiencies – iron, vitamin B12, and fat‑soluble vitamins due to chronic bleeding and malabsorption.

When to Seek Emergency Care

References

1. W. J. Ferguson, et al. “Zollinger‑Ellison syndrome: Epidemiology and clinical presentation.” J Clin Gastroenterol, 2020; 54(7): 543‑549. PMCID: PMC3654347.
2. American College of Gastroenterology. “Guideline for the Management of Peptic Ulcer Disease.” 2023. gi.org.
3. Mayo Clinic. “Zollinger‑Ellison syndrome.” Updated 2022. mayo.org.
4. National Cancer Institute. “Neuroendocrine Tumors Treatment (PDQ®)‑Health Professional Version.” 2024. cancer.gov.
5. World Health Organization. “Classification of Tumors of the Digestive System, 5th Edition.” 2024.
6. Cleveland Clinic. “Gastrinoma (Zollinger‑Ellison Syndrome) – Symptoms, Diagnosis, Treatment.” 2023. clevelandclinic.org.

```